Utama › Kanser Esofagus › Pennsylvania › Pittsburgh
Kajian klinikal Kanser Esofagus di Pittsburgh, PA
15 kajian untuk Kanser Esofagus sedang mencari peserta di lokasi dalam dan sekitar Pittsburgh (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Mengambil pesertaFasa 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Mengambil peserta
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Mengambil pesertaFasa 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Mengambil pesertaFasa 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Mengambil pesertaFasa 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Mengambil pesertaFasa 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Mengambil pesertaFasa 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Mengambil pesertaFasa 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Mengambil pesertaFasa 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
Mengambil peserta
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Mengambil pesertaFasa 2
- UPMC Hillman Cancer Center, Pittsburgh
Esophageal Cancer Risk Registry
Mengambil pesertaKajian pemerhatian
- Department of Cardiothoracic Surgery, Pittsburgh
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
Mengambil pesertaKajian pemerhatian
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh
- UPMC - Hillman Cancer Center, Pittsburgh
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Mengambil pesertaKajian pemerhatian
- Allegheny Health Network, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Mengambil pesertaFasa 1
- AHN West Penn Hospital, Pittsburgh
Kajian Kanser Esofagus di bandar lain
- Houston, TX36 kajian
- Boston, MA23 kajian
- New York City, NY22 kajian
- Nashville, TN19 kajian
- St. Louis, MO17 kajian
- Los Angeles, CA15 kajian
- Baldwin Park, CA14 kajian
- Grand Rapids, MI14 kajian
- Philadelphia, PA13 kajian
- San Antonio, TX12 kajian
- Rochester, MN11 kajian
- Arlington, VA11 kajian
Kajian lain di Pittsburgh
- Kanser Paru-paru Bukan Sel Kecil48 kajian
- Kanser (semua jenis)41 kajian
- Kanser Payudara39 kajian
- Kanser Kolorektal32 kajian
- Kanser Metastatik31 kajian
- Melanoma31 kajian
- Kanser Ovari30 kajian
- Kanser Endometrium23 kajian
- Kanser Prostat23 kajian
- Kanser Paru-paru23 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher22 kajian
- Strok22 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.